RVMDW
Revolution Medicines, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 13 ▲ Revolution Medicines announced positive topline results from its Pha…
- Apr 13 ▼ Revolution Medicines is conducting a $750 million common stock offer…
- Apr 13 ▼ Revolution Medicines is raising $250 million through a convertible s…
- Apr 15 Revolution Medicines is raising $1.44 billion through a public offer…
- Apr 15 ▼ Revolution Medicines is raising $500 million through a 0.50% convert…
- Apr 15 ▼ Mark A. Goldsmith, a director and officer of Revolution Medicines, i…
- Apr 16 Revolution Medicines raised approximately $1.65 billion through a pu…
- Apr 17 ▼ Revolution Medicines has issued $500 million in 0.50% convertible se…
- Aug 14 ▲ Short interest falls 27.5% to 836
- Aug 31 ▼ Short interest jumps 139.2% to 2.0K
- Sep 15 ▲ Short interest falls 64.8% to 703
- Oct 15 ▼ Short interest jumps 106.3% to 1.6K
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2026: 2 added (0 new), 1 trimmed or exited.
- Short sellersCOVERING
Short interest −15.9% to 1.3K shares. 1.0 days to cover, ≈0.0% of shares.
- TrendDOWNTREND
14% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Sculptor Capital LP | ADD | $12.2M |
| LMR Partners LLP | ADD | $47.5M |
| Sculptor Capital LP | TRIM | $6.7M |
| UBS Group AG | DOUBLED | $23.1K |
| OSAIC HOLDINGS, INC. | TRIM | $562.00 |
| Sculptor Capital LP | DOUBLED | $1.7M |
| Caption Management, LLC | DOUBLED | $926.7K |
| DRIEHAUS CAPITAL MANAGEMENT LLC | NEAR_EXIT | $34.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | None | None | No data | $462.0M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
8 filings · 1 bullish · 5 bearish · 2 neutral- BEARISH 8-KApr 17, 2026
Revolution Medicines has issued $500 million in 0.50% convertible senior notes due 2033, following…
Traders should be cautious of the significant dilution risk from this and recent capital raises. The stock may face downward pressure as investors assess the increased share count and leverage…
- NEUTRAL 8-KApr 16, 2026
Revolution Medicines raised approximately $1.65 billion through a public offering of 12.15 million…
Monitor the use of proceeds for advancement of product candidates and potential M&A activity. The convertible notes offering closing the next day could impact capital structure and future dilution…
- NEUTRAL 424B5Apr 15, 2026
Revolution Medicines is raising $1.44 billion through a public offering of 10.56 million common…
Monitor whether the concurrent convertible note offering closes, as this could add significant future dilution. The substantial dilution for new investors suggests caution, though the capital…
- BEARISH 424B5Apr 15, 2026
Revolution Medicines is raising $500 million through a 0.50% convertible senior notes offering due…
The significant debt issuance combined with substantial equity dilution from the concurrent stock offering creates substantial overhang on the stock. The 35% premium to current price for conversion…
All RVMDW filing & press-release reports (8)
- 8-K reportApr 17, 2026
- 8-K reportApr 16, 2026
- 424B5 reportApr 15, 2026
- 424B5 reportApr 15, 2026
- 144 reportApr 15, 2026
- 424B5 reportApr 13, 2026
- 424B5 reportApr 13, 2026
- 8-K reportApr 13, 2026